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Association of Vascular Risk Factors With β-Amyloid Peptide
and Tau Burdens in Cognitively Unimpaired Individuals
and Its Interaction With Vascular Medication Use
Theresa Köbe, PhD; Julie Gonneaud, PhD; Alexa Pichet Binette, MSc; Pierre-François Meyer, PhD; Melissa McSweeney, MSc;
Pedro Rosa-Neto, MD, PhD; John C. S. Breitner, MD, MPH; Judes Poirier, PhD, MD (Hon); Sylvia Villeneuve, PhD;
for the Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) Research Group

Abstract

Key Points

IMPORTANCE Vascular risk factors are associated with increased risk of Alzheimer disease (AD), but
it is unclear whether there is a direct association of these risk factors with AD pathogenesis.

Question Does cardiovascular
medication use moderate the
association of vascular risk factors with
Alzheimer disease pathogenesis as

OBJECTIVES To assess the associations of vascular risk factors with AD pathogenesis in
asymptomatic individuals, and to test whether this association is moderated among individuals who
use vascular medications.

measured by β-amyloid peptide and tau
burdens among individuals who are
cognitively unimpaired?

DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study used data from the

Findings In this cross-sectional study of

Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease

215 middle- and late-aged adults who

(PREVENT-AD) cohort of cognitively unimpaired individuals aged 55 to 82 years with a parental or

were cognitively unimpaired, use of

multiple-sibling history of sporadic AD, who were recruited via advertisement from the greater

vascular medications moderated an

Montreal, Quebec, Canada, metropolitan area. Participants were enrolled between September 9,

association of higher lipid levels, blood

2011, to May, 3, 2017, and stratified by use vs no use of vascular medications. Data were analyzed July

pressure, and combined vascular risk

1, 2018, to April 5, 2019.

scores with increased brain β-amyloid
peptide burden. Regarding tau burden,

MAIN OUTCOMES AND MEASURES Principal analyses investigated associations of total, high-

use of vascular medications moderated

density lipoprotein, and low-density lipoprotein cholesterol levels, systolic and diastolic blood

none but the association of combined

pressure, pulse pressure, and a combined vascular risk score (measured using the Framingham

vascular risk with higher entorhinal tau

Coronary Risk Profile) with global β-amyloid peptide (Aβ) and entorhinal tau burden as measured by

deposition.

positron emission tomography (PET). Potential moderating associations of use of vascular

Meaning This finding suggests that in

medications with these associations were examined. Secondary similar analyses considered
cerebrospinal fluid (CSF) Aβ1-42 and phosphorylated tau levels.

individuals at risk for Alzheimer disease,
treatment for common vascular risk
factors may moderate or mask the

RESULTS Among 215 participants (mean [SD] age, 62.3 [5.0] years; 161 [74.8%] women), 120
participants underwent PET, including 75 participants (62.5%) who were not using vascular

associations of these factors with
β-amyloid peptide burden.

medications, and 162 participants underwent CSF assessment, including 113 participants (69.8%)
who were not using vascular medications. There was an overlap of 67 participants who underwent
PET and CSF assessment. Interaction analyses showed that among participants not using vascular
medications, higher Aβ deposition as measured by PET was associated with higher total cholesterol
level (β = −0.002 [SE, 0.001]; P = .02), low-density lipoprotein cholesterol level (β = −0.002 [SE,

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

0.001]; P = .006), systolic blood pressure (β = −0.006 [SE, 0.002]; P = .02), pulse pressure
(β = −0.007 [SE, 0.002]; P = .004), and Framingham Coronary Risk Profile score (β = −0.038 [SE,
0.011]; P = .001), but such associations were absent in participants who used vascular medications.
Interactions were also found between vascular medication use and high-density lipoprotein
cholesterol (β = −3.302 [SE, 1.540]; P = .03), low-density lipoprotein cholesterol (β = 1.546 [SE,
0.754]; P = .04), and Framingham Coronary Risk Profile score (β = 23.102 [SE, 10.993]; P = .04) on
(continued)
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Abstract (continued)

Aβ1-42 burden as measured in CSF. Higher Framingham Coronary Risk Profile scores were associated
with reduced tau burden among participants using vascular medications but not among participants
not using vascular medications (interaction, β = −0.010 [SE, 0.005]; P = .046).
CONCLUSIONS AND RELEVANCE These findings corroborate previously reported associations of
vascular risk factors with Aβ burden but not tau burden. However, these associations were found
only among individuals who were not using vascular medications. These results suggest that
medication use or other control of vascular risk factors should be considered in Alzheimer disease
prevention trials.
JAMA Network Open. 2020;3(2):e1920780. doi:10.1001/jamanetworkopen.2019.20780

Introduction
The neuropathological hallmarks of Alzheimer disease (AD) include cerebral β-amyloid peptide (Aβ)
plaques and hyperphosphorylated tau neurofibrillary tangles. Vascular risk factors, such as
dyslipidemia and hypertension, are thought to modify AD risk by promoting both cardiovascular
disease and Aβ accumulation.1 While this dual vascular pathway hypothesis is attractive, results have
been mixed. Cholesterol levels and blood pressure (BP) outside of reference ranges, as well as
combined vascular risk scores, have been associated with increased Aβ burden in some studies,2-7
but other studies have had conflicting results.8,9 A few studies also found direct and indirect
associations of vascular risk factors with increased tau burden,8,10-12 potentially moderated through
Aβ burden; however, a 2009 study13 did not find these associations.
Such inconsistent results might be explained by potential moderation by vascular
medications.3,14 Depending on treatment duration and type,14,15 the use of statins and
antihypertensive drugs may be associated with providing protection against Aβ deposition.16,17
Participants using these vascular medications might even have experienced adverse effects of
vascular risk factors over many years, but successful treatment preceding data collection could
obscure the associations of these vascular risk factors with AD pathogenesis.
We examined whether use of vascular medications moderate the association of vascular risk
factors (ie, cholesterol levels, BP, and a combined vascular risk score) with factors associated with AD
pathogenesis (ie, Aβ and tau burdens) in middle- to late-aged individuals who were cognitively
unimpaired and had a family history of AD. A first-degree family history of AD is associated with a 2to 3-fold increased risk for AD,18 making individuals with such a family history of AD ideal for studying
mechanisms associated with AD at an asymptomatic stage, which is the optimal time for prevention.
Our principal hypothesis was that an association between vascular risk factors and AD pathogenesis
would be stronger among individuals who did not use any medications to treat vascular risk factors
(untreated cohort) than in individuals using vascular medications (treated cohort).

Methods
Participants and Study Design
Participants were recruited from the Presymptomatic Evaluation of Experimental or Novel
Treatments for Alzheimer Disease (PREVENT-AD) cohort, an ongoing longitudinal observational
study comprising a total sample size of 385 individuals.19 Inclusion criteria for PREVENT-AD were
having parental or multiple-sibling history of AD-like dementia, being 60 years or older at enrollment
or age 55 to 59 years if that was fewer than 15 years from the age of symptomatic dementia onset of
a sibling or parent, having no major neurological diseases, and having unimpaired cognition. All
participants exhibited unimpaired cognitive and functional scores on the Montreal Cognitive
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Assessment20 and the Clinical Dementia Rating21 before exhibiting unimpaired neuropsychological
function on the Repeatable Battery for the Assessment of Neuropsychological Status.22 Fifteen
individuals with ambiguous Repeatable Battery for the Assessment of Neuropsychological Status or
Montreal Cognitive Assessment results were considered unimpaired after more extensive
neuropsychological testing, as reviewed by neuropsychologists and physicians (including J.G.,
J.C.S.B, and S.V.). A flowchart of this study is presented in eFigure 1 in the Supplement.
These cross-sectional analyses considered a subsample of PREVENT-AD participants who had
data on Aβ and tau burden, measured by positron emission tomography (PET) or cerebrospinal fluid
(CSF) assessment. Analyses were conducted separately in participants who had PET or CSF
assessment data. Participants were dichotomized further into those who did not report use of
medications to remediate vascular risk factors (untreated cohort) vs those who reported using such
medications, including lipid-lowering medications, antihypertensive medications, or both, at
enrollment (treated cohort). A joint category of all participants who used vascular medications was
created because dyslipidemia and hypertension often co-occur,23,24 and vascular medication may act
on multiple pathways.25 All procedures followed the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) reporting guidelines for cross-sectional studies.
This study was approved by the McGill University Faculty of Medicine institutional review board.
All participants received detailed study instructions and gave written informed consent prior to
participation.

Vascular Risk Factor Assessment
All participants underwent medical examinations, and nonfasting venous blood samples were taken
at enrollment. Tests included assessment of plasma lipid concentrations and BP (eAppendix in the
Supplement). Plasma levels of total, high-density lipoprotein (HDL), and low-density lipoprotein
(LDL) cholesterol were measured using the CHOD-PAP method (Synchron LX, UniCel DxC 600/800
System and Synchron Systems Lipid Calibrator; Beckman Coulter). Blood pressure was assessed in
a standardized procedure using an automatic sphygmomanometer (Connex ProBP 3400; Welch
Allyn) while participants were seated. Pulse pressure was calculated as the difference between
diastolic and systolic BP.

Combined Vascular Risk Score
A variety of combined risk scores incorporating multiple vascular risk factors have been previously
developed to estimate overall cardiovascular and coronary disease risk with the intent to detect
individuals who are at increased risk with greater sensitivity than is possible by assessment of single
risk factors.26 We used the Framingham Coronary Risk Profile (FCRP), a widely used index that
estimates 10-year risk of coronary heart disease.26 The FCRP score is calculated as a sum of weighted
measures of age, sex, systolic and diastolic BP, HDL and LDL cholesterol levels, smoking status, and
diabetes status.26 Higher scores indicate greater risk.

Assessments of Aβ and Tau Burdens
We performed PET scans using fluorine 18–labeled NAV4694 (NAV) for Aβ level and fluorine
18–labeled AV-1451 (Flortaucipir) for tau level estimation at the McConnell Brain Imaging Centre of the
Montreal Neurological Institute, Montreal, Quebec, Canada, on a high-resolution PET scanner
(Siemens). Static acquisition frames were obtained at 40 to 70 minutes after injection for Aβ and at
80 to 100 minutes after injection for tau. Structural magnetic resonance imaging (MRI) scans were
T1-weighted and acquired on a 3-T Siemens Trio scanner at the Brain Imaging Centre of the Douglas
Mental Health Institute, Montreal, using 2300 milliseconds for repetition time, 2.98 milliseconds for
echo time, 176 slices, and slice thickness of 1 mm.
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Cerebrospinal fluid samples were obtained by lumbar puncture in the morning under fasting
conditions. Concentrations of Aβ1-42 and phosphorylated tau (pTau) were measured by enzymelinked immunosorbent assay (INNOTEST; Fujirebio) as described previously.27 More information
about PET and CSF assessment is available in the eAppendix in the Supplement.

PET Processing
Data from PET were preprocessed using a standard pipeline.28 Briefly, 4-dimensional PET images
were calculated for means and linearly coregistered to each individual’s T1-weighted images before
being masked to exclude CSF binding and smoothed with a 6-mm3 Gaussian kernel. Individual
T1-weighted images were segmented based on the Desikan-Killiany atlas using the semiautomated
FreeSurfer processing stream version 5.3 (Martinos Center for Biomedical Imaging). Standardized
uptake value ratios (SUVR) were computed for Aβ burden29 by dividing the tracer uptake by
cerebellar gray matter uptake and for tau burden30 by dividing the tracer uptake by inferior
cerebellar gray matter uptake. We restricted the region of interest analyses to FreeSurfer-derived
AD-typical regions, in this case, weighted mean SUVRs from the frontal, temporal, parietal, and
posterior cingulate cortices for Aβ quantification29 and from the entorhinal cortex for tau
quantification.31

Genotyping
Genomic DNA was extracted from whole blood, and apolipoprotein E (APOE) genotype was
determined using the PyroMark Q96 pyrosequencer (Qiagen), as described previously.27 Participants
were classified as APOE ε4 carriers (ie, those who had 1-2 ε4 alleles) or noncarriers.

Statistical Analysis
Group differences between the treated vs untreated cohorts in the PET and in the CSF assessment
groups were tested using unpaired t tests for normally distributed continuous variables, MannWhitney U tests for nonnormally distributed continuous variables, or χ2 tests for categorial variables.
Individuals with missing values were excluded from respective analyses.
To test for the main association of vascular risk factors with AD brain pathogenesis as measured
by Aβ or tau deposition, we performed multiple linear regression analyses in untreated and treated
cohorts combined. Models included age, sex, vascular medication status (ie, using medication or
not), and time difference between vascular risk factor assessments and undergoing PET as
covariates. A second model tested for statistical interaction between vascular risk factors and
vascular medication status in association with AD brain pathogenesis, retaining the same covariates
as in the first model. Finally, we examined associations of vascular risk factors with AD brain
pathogenesis separately for treated and untreated cohorts using independent linear regressions and
the same covariates as in the second model. On observing a significant interaction, subgroup
analyses were interpreted.
To investigate whether imaging findings could be reproduced using CSF biomarkers, we
performed the same multiple regression and within-group analyses using CSF Aβ1-42 and pTau levels
as dependent variables. While PET and CSF Aβ and tau biomarkers are known to be correlated, they
do not capture the exact same pathological components (soluble vs nonsoluble); thus, PET and CSF
may be considered as complementary markers.32,33
The mean (range) time delays between assessments of vascular risk factors at enrollment and
assessment of Aβ and tau were 45 (3-75) months for participants who underwent PET and 11 (0-62)
months for participants who underwent CSF assessment. Vascular risk factors were always assessed
prior to PET or CSF assessment. Although we did not expect noteworthy changes in SUVRs as
measured by PET within 45 months,34 we adjusted all statistical models for the time between
vascular risk factors and PET or CSF assessment. To explore potential modifying associations of APOE
ε4 status, we performed identical analyses that included APOE ε4 status as an additional covariate
in the models.
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Under the assumption that both lipid and BP biomarkers would be associated with AD
pathogenesis, we ran an exploratory regression model including both types of risk factors to test
whether they were independently associated with AD pathogenesis. Supplementary analyses
included linear regression to test whether longer treatment durations for dyslipidemia or
hypertension were associated with reduced AD pathological burden. Treatment duration before
enrollment in PREVENT-AD was reported by participants through an online questionnaire (response
rate, 88%).
Analyses were performed with SPSS statistical software version 24.0 (IBM Corp). Two-tailed P
values less than .05 were considered statistically significant. Analyses were not corrected for multiple
comparisons because of complementarity of the vascular risk factor measures. Individual results
should therefore be interpreted with caution.

Results
Participant Characteristics
The study sample included 215 participants (mean [SD] age, 62.3 [5.0], years; 161 [74.9%] women),
87 of whom (40.5%) were APOE ε4 carriers. Among 215 participants, 120 participants underwent
PET, including 75 participants (62.5%) who were not using vascular medications, and 162 participants
underwent CSF assessment, including 113 participants (69.8%) who were not using vascular
medications. There was an overlap of 67 participants who underwent PET and CSF assessment.
Among both groups, a total of 69 participants (mean [SD] age, 63.4 [4.5] years; 47 [68.1%] women)
used vascular medications, and 146 participants (mean [SD] age, 61.8 [5.1] years; 114 [78.1%] women)
did not use vascular medications. Compared with participants in the untreated cohort, participants
in the treated cohort had lower mean (SD) concentrations of total cholesterol (217.43 [33.2] mg/dL vs
189.31 [39.1] mg/dL; P < .001) and LDL cholesterol (124.96 [27.29] mg/dL vs 95.75 [36.20] mg/dL;
P < .001) but higher systolic BP (123.77 [14.4] mm Hg vs 131.67 [12.7] mm Hg; P < .001) and pulse
pressure (50.88 [10.8] mm Hg vs 55.81 [12.7] mm Hg; P = .003) (to convert cholesterol to millimoles
per liter, multiply by 0.0259). Levels of Aβ and tau were comparable in participants who underwent
PET and those who underwent CSF assessment regardless of treatment status. Complete participant
characteristics are presented in Table 1.
Participants were generally in good health, but nevertheless presented a wide range of vascular
risk factors. The predominant vascular risk factors recorded in the total cohort were total cholesterol
level more than 200 mg/dL (124 participants [57.9%]), LDL cholesterol level more than 130 mg/dL
(72 participants [34.0%]), systolic BP 130 mm Hg or higher (83 participants [38.6%]), diastolic BP 80
mm Hg or higher (66 participants [30.1%]) and body mass index (calculated as weight in kilograms
divided by height in meters squared) more than 30 (47 participants [22.0%]). Approximately 4% of
participants had diabetes, and approximately 3% of participants reported current smoking.

Associations of Vascular Risk Factors With Global Aβ and Entorhinal Tau SUVR
Measured by PET
Among participants who underwent PET, no association of vascular risk factors, either as individual
factors or combined as FCRP score, was found with global cerebral Aβ deposition. However,
interaction analyses showed that among participants not using vascular medications, higher Aβ
deposition as measured by PET was associated with higher total cholesterol (unstandardized
β = −0.002 [SE, 0.001]; P = .02), low-density lipoprotein cholesterol (β = −0.002 [SE, 0.001];
P = .006), systolic BP (β = −0.006 [SE, 0.002]; P = .02), pulse pressure (β = −0.007 [SE, 0.002];
P = .004), and Framingham Coronary Risk Profile score (β = −0.038 [SE, 0.011]; P = .001), but such
associations were absent in participants who used vascular medications (Figure 1 and Table 2).
Specifically, in untreated participants, a 50-mg/dL increase in total cholesterol level was associated
with an increase of 0.10 in Aβ SUVR, and a 50-mg/dL increase in LDL cholesterol level was associated
with an increase of 0.20 in Aβ SUVR. A 10–mm Hg increase in systolic BP was associated with a 0.06
JAMA Network Open. 2020;3(2):e1920780. doi:10.1001/jamanetworkopen.2019.20780 (Reprinted)
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increase in Aβ SUVR, and a 10–mm Hg increase in pulse pressure was associated with a 0.10 increase
in Aβ SUVR. A 1-unit increase in FCRP score was associated with a 0.03 increase in Aβ SUVR. No
similar associations were found in the treated cohort of participants who underwent PET. These
results remained largely unchanged when APOE ε4 status was added as an additional covariate
(eTable 1 in the Supplement).

Table 1. Participant Characteristics
Participants, Mean (SD) [Range] (N = 215)a
Underwent PET (n = 120)

Underwent CSF Assessment (n = 162)

Characteristic

Untreated Cohort
(n = 75)

Treated Cohort
(n = 45)

P Value

Untreated Cohort
(n = 113)

Treated Cohort
(n = 49)

P Value

Women, No. (%)

56 (74.7)

33 (73.3)

.52b

88 (77.9)

29 (59.2)

.02b

Age, y

63 (4.8)
[55-78]

64 (4.4)
[57-73]

.045c

62 (5.2)
[55-82]

63 (4.6)
[55-74]

.05d

Education, y

15 (3.2)
[7-24]

15 (3.4)
[7-24]

.51d

16 (3.0)
[10-27]

14 (3.1)
[7-20]

.09c

MOCA score

28.2 (1.5)
[24-30]

28.2 (1.6)
[24-30]

.86c

27.9 (1.5)
[23-30]

28.2 (1.5)
[25-30]

.39c

APOE ε4 carrier, No. (%)

28 (37.3)

21 (46.7)

.31b

40 (35.4)

24 (49.0)

.12b

Total

216.13 (36.0)
[135.35-320.96]e

188.37 (37.4)
[127.61-278.42]

<.001c

217.76 (32.5)
[143.08-320.96]e

186.42 (39.1)
[112.14-274.56]e

<.001c

HDL

60.31 (16.1)
[28.62-99.00]e

55.56 (13.2)
[34.42-96.29]

.10c

63.15 (17.1)
[28.62-121.81]e

57.55 (15.4)
[34.42-110.60]e

.05c

LDL

126.25 (28.1)
[66.51-223.13]f

94.84 (38.2)
[38.28-194.12]g

<.001c

125.21 (28.0)
[61.49-223.13]h

91.65 (33.4)
[38.28-167.44]h

<.001c

Systolic

125.5 (13.3)
[100-158]

134.2 (12.4)
[107-168]

.001c

123.6 (14.9)
[92-162]

131.0 (12.3)
[110-164]

.003c

Diastolic

73.2 (7.5)
[60-94]

75.5 (8.3)
[60-93]

.12d

73.0 (8.7)
[52-98]

75.4 (8.8)
[58-93]

.09d

Pulse pressure,
mm Hg

52.3 (10.8)
[24-80]

58.7 (12.7)
[35-88]

.004c

50.8 (10.9)
[26-80]

55.7 (12.2)
[32-84]

.01c

FCRP score

5.9 (2.6)
[1-12]g

6.7 (2.9)
[1-12]

.16d

5.7 (2.5)
[0-12]h

5.7 (2.3)
[1-11]h

.97d

Aβ, [18F]NAV4694 SUVR,
median (IQR) [range]

1.2 (1.14-1.31)
[1.1-2.3]

1.22 (1.15-1.33)
[1.0-2.8]

.68d

NA

NA

NA

Tau, [18F]AV-1451 SUVR,
median (IQR) [range]

1.05 (0.99-1.13)
[0.7-1.7]

1.04 (0.99-1.16)
[0.9-1.4]e

.92d

NA

NA

NA

Aβ1-42, pg/mL

NA

NA

NA

1192 (275)
[479-1760]i

1138 (261)
[501-1568]j

.27c

Phosphorylated tau, pg/mL

NA

NA

NA

47.5 (16.0)
[12.1-98.2]e

48.8 (17.9)
[17.8-114.4]

.85d

Lipid-lowering drugs

NA

17 (38)

NA

NA

21 (43)

NA

Antihypertensive drugs

NA

14 (31)

NA

NA

12 (24)

NA

Lipid-lowering and
antihypertensive drugs

NA

14 (31)

NA

NA

16 (33)

NA

Duration of medication use, y

NA

10.4 (8.7)
[1-36]g

NA

NA

9.0 (5.7)
[1-21]k

NA

Plasma cholesterol level,
mg/dL

Arterial blood pressure,
mm Hg

Medication use, No. (%)

Abbreviations: Aβ, β-amyloid; CSF, cerebrospinal fluid; 18F, fluorine 18; FCRP,
Framingham Coronary Risk Profile; HDL, high-density lipoprotein; IQR, interquartile
range; LDL, low-density lipoprotein; MOCA, Montreal Cognitive Assessment; NA, not
applicable; PET, positron emission tomography; SUVR, standard uptake value ratio.

d

Calculated with Mann-Whitney U test.

e

Missing data for 1 participant.

f

Missing data for 3 participants.

g

Missing data for 2 participants.

h

Missing data for 4 participants.

i

Missing data for 15 participants.

j

Missing data for 5 participants.

k

Missing data for 8 participants.

SI conversion factor: To convert cholesterol to millimoles per liter, multiply by 0.0259.
a

There were 67 participants (31%) who underwent both PET and CSF assessments and
were included in both analyses, including 42 participants in the untreated cohorts and
25 participants in the treated cohorts.

b

Calculated with χ2 test.

c

Calculated with unpaired t test.
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When included in the same regression model, we found independent associations of Aβ burden
with LDL cholesterol level (β = 0.003 [SE, 0.001], P = .006) and pulse pressure (β = 0.010 [SE,
0.003], P = .002) in the untreated cohort. Within the treated group, there were no associations of
treatment duration with Aβ SUVR after adjusting for age and sex (β = −0.007 [SE, 0.004]; P = .09).
In contrast to Aβ, there were no main associations of single vascular risk factors with tau
deposition, and there were no interactions between single vascular risk factors and vascular
medication associated with tau deposition in the entorhinal cortex. An interaction was found
between FCRP score and medication use associated with entorhinal tau. Within-group analyses of
the treated cohort suggested that a 1-unit increase in the FCRP score was associated with a 0.02
SUVR decrease in entorhinal tau (β = −0.010 [SE, 0.005]; P = .046) (Table 3; eFigure 2 in the
Supplement). This isolated association lost significance with adjustment for APOE ε4 status (eTable 2
in the Supplement).

Figure 1. Associations of Vascular Risk Factors and β-Amyloid Peptide (Aβ) Burden as Measured by Positron Emission Tomography
A Lipid measures
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Associations of Vascular Risk Factors With Aβ1-42 and pTau Levels Measured
by CSF Assessment
Comparable analyses using CSF assessments found negative associations of lower Aβ1-42
concentration, representing higher Aβ burden, with higher total cholesterol (β = −2.010 [SE, 0.641],
P = .002) and HDL cholesterol (β = −3.525 [SE, 1.474]; P = .02) levels. Interactions were also found
between vascular medication use and high-density lipoprotein cholesterol (β = −3.302 [SE, 1.540];
P = .03), low-density lipoprotein cholesterol (β = 1.546 [SE, 0.754]; P = .04), and Framingham
Coronary Risk Profile score (β = 23.102 [SE, 10.993]; P = .04) on Aβ1-42 burden as measured in CSF.
More specifically, a 50-mg/dL increase in LDL cholesterol was associated with a 164-pg/mL decrease
in Aβ1-42 levels (thus higher Aβ burden) in the untreated cohort. No significant associations were
found between FCRP score and Aβ1-42 in the treated or untreated cohorts. In the treated cohort, we
found that a 50-mg/dL increase in HDL cholesterol level was associated with a 393-pg/mL decrease
in Aβ1-42, reflecting higher Aβ burden (Figure 2; eTable 3 in the Supplement). After adjustment for
APOE ε4 status, only the associations with LDL cholesterol level remained significant within the
untreated cohort (eTable 4 in the Supplement).
No association was found between treatment duration and Aβ1-42 concentration after
adjusting for age and sex (β = 0.339 [SE, 7.971]; P = .97). Consistent with the PET data, no main
associations of vascular risk factors and no interactions between vascular risk factors and vascular
medication use were found with pTau levels as measured by CSF assessment (eFigure 3 and eTable 5
in the Supplement) or after correction for APOE ε4 status (eTable 6 in the Supplement).

Table 2. Associations of Vascular Risk Factors With Global Cerebral Aβ Burden Measured by Positron Emission Tomography
Aβ Burden, Unstandardized β (SE) [P Value]
Cholesterol Level
Variable

Blood Pressure

Total

HDL

LDL

Systolic

Diastolic

Pulse Pressure

FCRP Score

Age

0.014 (0.006)
[.02]

0.015 (0.006)
[.02]

0.015 (0.006)
[.02]

0.013 (0.006)
[.047]

0.015 (0.006)
[.02]

0.012 (0.007)
[.06]

0.015 (0.007)
[.03]

Sex

−0.058 (0.067)
[.39]

−0.061 (0.069)
[.38]

−0.090 (0.069)
[.20]

−0.036 (0.065)
[.58]

−0.041 (0.065)
[.54]

−0.034 (0.065)
[.60]

−0.080 (0.072)
[.27]

Time difference

−0.002 (0.002)
[.15]

−0.002 (0.002)
[.14]

−0.002 (0.002)
[.18]

−0.002 (0.002)
[.12]

−0.002 (0.002)
[.12]

−0.002 (0.002)
[.12]

−0.003 (0.002)
[.11]

Medication

0.009 (0.064)
[.89]

−0.008 (0.061)
[.89]

0.033 (0.068)
[.63]

−0.033 (0.062)
[.60]

−0.015 (0.060)
[.80]

−0.032 (0.061)
[.60]

−0.008 (0.062)
[.90]

Vascular risk factor

0.001 (0.001)
[.28]

0.002 (0.002)
[.38]

0.001 (0.001)
[.17]

0.002 (0.002)
[.34]

−0.001 (0.004)
[.87]

0.003 (0.003)
[.23]

0.003 (0.012)
[.82]

−0.002 (0.001)
[.02]

0.001 (0.002)
[.51]

−0.002 (0.001)
[.006]

−0.006 (0.002)
[.02]

<−0.001 (0.004)
[.98]

−0.007 (0.002)
[.004]

−0.038 (0.011)
[.001]

Age

0.019 (0.007)
[.01]

0.020 (0.008)
[.009]

0.019 (.007)
[.01]

0.016 (0.007)
[.04]

0.020 (0.007)
[.008]

0.014 (0.007)
[.047]

0.014 (0.008)
[.09]

Sex

0.018 (0.082)
[.82]

0.063 (0.089)
[.48]

0.021 (0.081)
[.80]

0.078 (0.078)
[.32]

0.060 (0.081)
[.46]

0.100 (0.077)
[.20]

0.021 (0.084)
[.80]

Time difference

−0.002 (0.002)
[.18]

−0.002 (0.002)
[.19]

−0.002 (0.002)
[.30]

−0.002 (0.002)
[.25]

−0.002 (0.002)
[.18]

−0.002 (0.002)
[.30]

−0.003 (0.002)
[.13]

Vascular risk factor

0.002 (0.001)
[.04]

<−0.001 (0.002)
[.88]

0.004 (0.001)
[.004]

0.006 (0.003)
[.02]

−0.001 (0.005)
[.80]

0.010 (0.003)
[.002]

0.033 (0.015)
[.03]

Age

0.006 (0.011)
[.56]

0.007 (0.011)
[.50]

0.009 (0.011)
[.43]

0.012 (0.012)
[.32]

0.006 (0.011)
[.58]

0.012 (0.012)
[.33]

0.014 (0.011)
[.20]

Sex

−0.175 (0.112)
[.13]

−0.220 (0.111)
[.05]

−0.275 (0.117)
[.02]

−0.192 (0.109)
[.09]

−0.194 (0.111)
[.09]

−0.188 (0.109)
[.09]

−0.205 (0.122)
[.10]

Time difference

−0.004 (0.003)
[.24]

−0.003 (0.003)
[.30]

−0.005 (0.003)
[.12]

−0.003 (0.003)
[.37]

−0.003 (0.003)
[.31]

−0.002 (0.003)
[.40]

−0.004 (0.003)
[.14]

Vascular risk factor

−0.001 (0.001)
[.41]

0.005 (0.004)
[.21]

−0.001 (0.001)
[.47]

−0.005 (0.004)
[.25]

−.002 (0.006)
[.77]

−0.004 (0.004)
[.33]

−0.033 (0.019)
[.09]

Model 1

Model 2: interaction of vascular
risk factor × medicationa
Untreated cohort

Treated cohort

Abbreviations: Aβ, β-amyloid peptide; FCRP, Framingham Coronary Risk Profile; HDL,
high-density lipoprotein; LDL, low-density lipoprotein.

a

Adjusted for all covariates included in model 1.
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Discussion
This cross-sectional study found that cardiovascular medication use moderated the associations of
vascular risk factors with Aβ burden among middle- to late-aged individuals who were cognitively
unimpaired but at risk of AD. Specifically, we observed associations of higher total and LDL
cholesterol levels, systolic BP, pulse pressure, and a composite of vascular risk factors, FCRP score,
with increased cerebral Aβ deposition in individuals who did not use vascular medications.
Importantly, these associations were not present in individuals who used vascular medications. The
associations were not significant when participants were pooled together regardless of their
medication status. The findings with LDL cholesterol levels and FCRP score were replicated when Aβ
burden was measured using CSF Aβ1-42 levels. We did not observe associations between individual
vascular risk factors and cerebral or CSF tau accumulation, but vascular medication use showed an
interaction with the association of FCRP score with tau deposition as measured by PET, such that
higher FCRP scores were associated with reduced tau deposition in the treated cohort.
While some neuroimaging and autopsy studies have revealed no association of vascular health
with Aβ deposition,8,35 others have shown detrimental associations of higher cholesterol levels2 and
BP4,36 with Aβ accumulation. Our findings may explain these inconsistencies by showing that
vascular medication use moderated those associations such that, in our sample, such associations
were detectable only in untreated individuals. Similarly, a 2014 study6 reported that vascular risk
factor burden and Aβ were associated with reduced cortical thickness, particularly in individuals who
did not use cholesterol-lowering medications, compared with individuals who were treated for
hyperlipidemia.

Table 3. Associations of Vascular Risk Factors With Entorhinal Tau Burden as Measured by Positron Emission Tomography
Tau Burden, Unstandardized β (SE) [P Value]
Cholesterol Level
Variable

Blood Pressure

Total

HDL

LDL

Systolic

Diastolic

Pulse Pressure

FCRP Score

Age

0.007 (0.003)
[.008]

0.008 (0.003)
[.006]

0.008 (0.003)
[.006]

0.008 (0.003)
[.01]

0.008 (0.003)
[.006]

0.007 (0.003)
[.01]

0.010 (0.003)
[.001]

Sex

0.018 (0.029)
[.54]

<0.001 (0.030)
[>.99]

0.009 (0.031)
[.76]

0.016 (0.029)
[.57]

0.017 (0.029)
[.56]

0.017 (0.029)
[.56]

0.023 (0.031)
[.47]

Time difference

<−0.001 (0.001)
[.93]

<0.001 (0.001)
[.97]

<0.001 (0.001)
[.86]

<−0.001 (0.001)
[.96]

<−0.001 (0.001)
[.96]

<−0.001 (0.001)
[.97]

<−0.001 (0.001)
[.96]

Medication

−0.012 (0.028)
[.68]

−0.006 (0.026)
[.83]

−0.011 (0.030)
[.72]

−0.010 (0.027)
[.72]

−0.009 (0.027)
[.74]

−0.012 (0.027)
[.66]

−0.005 (0.027)
[.85]

Vascular risk factor

<−0.001 (<0.001)
[.95]

0.002 (0.001)
[.07]

<−0.001 (<0.001)
[.93]

<0.001 (0.001)
[.94]

−0.001 (0.002)
[.66]

<0.001 (0.001)
[.82]

−0.009 (0.005)
[.09]

<−0.001 (<0.001)
[.56]

0.001 (0.001)
[.30]

−0.001 (0.001)
[.35]

−0.001 (0.001)
[.35]

<0.001 (0.002)
[.93]

−0.001 (0.001)
[.35]

−0.010 (0.005)
[.046]

Age

0.007 (0.004)
[.06]

0.007 (0.004)
[.06]

0.007 (0.004)
[.05]

0.006 (0.004)
[.08]

0.007 (.004)
[.048]

0.006 (0.004)
[.10]

0.007 (0.004)
[.07]

Sex

0.061 (0.040)
[.13]

0.056 (0.042)
[.19]

0.059 (0.041)
[.15]

0.063 (0.039)
[.11]

0.061 (0.038)
[.12]

0.067 (0.039)
[.09]

0.061 (0.041)
[.14]

Time difference

<0.001 (0.001)
[.89]

<0.001 (0.001)
[.86]

<0.001 (0.001)
[.84]

<0.001 (0.001)
[.80]

<0.001 (0.001)
[.85]

<0.001 (0.001)
[.75]

<0.001 (0.001)
[.86]

Vascular risk factor

<0.001 (<0.001)
[.96]

<0.001 (0.001)
[.72]

<0.001 (0.001)
[.62]

0.001 (0.001)
[.51]

−0.001 (0.002)
[.76]

0.002 (0.002)
[.30]

<0.001 (0.007)
[.97]

Age

0.009 (0.004)
[.03]

0.010 (0.004)
[.02]

0.011 (0.004)
[.01]

0.012 (0.005)
[.01]

0.009 (0.004)
[.04]

0.012 (0.005)
[.02]

0.014 (0.004)
[.001]

Sex

−0.056 (0.042)
[.19]

−0.081 (0.038)
[.04]

−0.089 (0.043)
[.046]

−0.057 (0.040)
[.16]

−0.060 (0.041)
[.15]

−0.057 (0.041)
[.17]

−0.044 (0.042)
[.30]

Time difference

−0.001 (0.001)
[.52]

−0.001 (0.001)
[.49]

−0.002 (0.001)
[.17]

−0.001 (0.001)
[.62]

−0.001 (0.001)
[.53]

<0.001 (0.001)
[.64]

−0.001 (0.001)
[.17]

Vascular risk factor

<0.001 (0.001)
[.76]

0.003 (0.001)
[.01]

<0.001 (<0.001)
[.46]

−0.002 (0.002)
[.24]

−0.001 (0.002)
[.64]

−0.001 (0.002)
[.42]

−0.019 (0.007)
[.006]

Model 1

Model 2: interaction of vascular
risk factor × medicationa
Untreated cohort

Treated cohort

Abbreviations: FCRP, Framingham Coronary Risk Profile; HDL, high-density lipoprotein;
LDL, low-density lipoprotein.

a

Adjusted for all covariates included in model 1.
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Our finding that lipid-lowering and antihypertensive medications moderated the associations
of vascular risk factors with Aβ burden could have clinical implications. It has been suggested that
cardiovascular medication might reduce AD risk by lowering arterial stiffness, leading to increased
cerebral blood flow and Aβ clearance.16,37 However, results from a randomized clinical trial38 and a
meta-analysis of cohort studies39 have been mixed. Other factors, such as treatment duration,
participants’ age at treatment onset, and medication type, appear to be important to the association
of vascular risk factor burden with AD-related end points.6,15 Interestingly, the mean Aβ burden was
similar in our treated and untreated cohorts. An alternative explanation for why an association of
vascular risk factors with Aβ burden was not observed in treated participants might be that vascular
risk factors were successfully lowered in most treated participants, but Aβ deposition had started
before treatment onset. Figure 1 suggests this, at least with lipid levels: the treated cohort had
cholesterol levels within reference ranges, but they may still have experienced adverse effects of
their hypercholesterolemia before it was treated. This question may depend also on their medication
type, timing, and duration.

Figure 2. Associations of Vascular Risk Factors With β-Amyloid Peptide (Aβ) Burden as Measured by Cerebrospinal Fluid Assessment
A Lipid measures
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value of the vascular risk factor; BP, blood pressure; HDL, high-density lipoprotein; and
LDL, low-density lipoprotein. To convert cholesterol to millimoles per liter, multiply
by 0.0259.
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The elevated AD risk in our study participants should render them well suited for analyses
examining the associations of vascular risk factors with AD pathogenesis. Different time points of
assessment of vascular risk factors in life might also influence their association with Aβ burden. For
example, vascular risk factors in midlife (age ⱕ70 years) may be associated with increased AD risk
and pathogenesis.5,40 Our results from a cohort of participants in middle to late age (mean age, 62
years) support these findings.
Although dyslipidemia and hypertension often co-occur,23,24 including both LDL cholesterol
level and pulse pressure as factors associated with cerebral Aβ burden in a single regression model
did not change our findings, suggesting that these factors were independently associated with the
outcome. However, the cross-sectional nature of our analyses makes it possible that the observed
associations were inversely related, so that Aβ burden might be associated with altered intracellular
vesicle trafficking and metabolic cholesterol homeostasis41 or vasopressor actions.42
The strongest known genetic AD risk factor, APOE ε4, has been found to be associated with lipid
metabolism,43 vasculature,44 Aβ deposition,45 and moderating the associations of vascular risk
factors with AD pathogenesis.3,46 However, some studies have reported conflicting results.7,8,40 In
our study, associations of vascular risk factors with Aβ burden measured using PET remained after
correction for APOE ε4 status, as has been reported previously.7,40 However, findings regarding CSF
Aβ1-42 levels were only partially independent of APOE ε4 status, suggesting that a potential
interaction between genetics and vascular risk factors associated with AD pathogenesis should be
further investigated.
It has been argued that composite vascular risk scores are more sensitive measures for
detecting associations of vascular risk factors with Aβ burden,6,7,40 although this has not been
consistently confirmed.12,47 In our study, the combined FCRP score, LDL cholesterol level, and pulse
pressure were the strongest factors associated with presymptomatic AD pathogenesis, but all of
these factors had similar associations with Aβ burden, which does not suggest superior sensitivity of
the FCRP score compared with single vascular risk factors. One reason for these results might be that
our study sample included very few individuals with diabetic comorbidities or smokers, which are
both included in the calculation of FCRP score.
With regard to tau, two 2019 studies of older adults who were cognitively unimpaired but who
had a mean age 10 years older than participants from the PREVENT-AD cohort reported that higher
vascular risk factor burden was associated with increased tau burden in the brain12 and CSF.48 We
found only 1 interaction between vascular medication use and the FCRP score associated with
cerebral tau burden, which unexpectedly suggested that higher vascular risk factor burden was
associated with lower tau deposition in the treated cohort. This isolated result could suggest that tau
burden is less sensitive to vascular risk factors than Aβ burden and that a combined vascular risk
score may be needed to show any association. However, we should note that the levels of cerebral
tau in our relatively young cohort were fairly low compared with cerebral Aβ levels; therefore,
associations of vascular risk factors and tau burden may have been more difficult to detect.
Furthermore, the association of vascular risk factors with tau was no longer significant when we
controlled for APOE ε4 status, drawing into question the strength of this individual association.
Further investigations are needed to better understand whether and how vascular risk factors are
associated with tau burden in the early AD continuum, and these inquiries should consider
confounding factors, such as medication use.

Strengths and Limitations
Our study has some strengths, including its reliance on middle- to late-aged individuals at risk for AD,
thereby perhaps exposing events in the initial accumulation of Aβ burden, that is, a time when
vascular risk factors may remain a promising target for disease prevention. The fact that PET findings
were substantiated, at least in part, by observations in CSF biomarkers associated with AD lends
further credence to the association of vascular risk factors with Aβ burden in such individuals.
Although we adjusted all models for the time difference between assessments of vascular risk factors
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and assessments of biomarkers associated with AD pathogenesis, the discord in findings with PET
and CSF assessment might reflect additional progression of AD stage at the time of PET
assessment,49 which was conducted a mean of 34 months after the CSF assessment. Different PET
and CSF findings might also reflect the measurement of different components of Aβ burden.49 The
prevalence of vascular risk factors in our cohort was generally comparable to that of the general US
population,50 except that current smoking status was approximately 10-fold lower in the
PREVENT-AD cohort, suggesting that our results are extendible to further populations.
Our study also has some limitations. We cannot exclude the possibility that participants in the
treated cohort may have had healthier lifestyles (eg, more regular exercise, maintaining healthy weight,
reduced alcohol consumption and smoking) because of an increased awareness of health concerns.
Such health consciousness may also have influenced our results. Other limitations of the study include
its cross-sectional design and that BP values were assessed from only 1 measurement instead of determining a mean of multiple measurements at enrollment. Studies with larger sample sizes are warranted
to investigate sex-specific associations of vascular risk factors with AD pathogenesis.

Conclusions
The findings of this cross-sectional study suggest that an individual’s use of vascular medications is
an important consideration when studying any association of vascular risk factors and AD
pathogenesis. Our findings also suggest the importance of targeting both systemic vascular burden
and Aβ burden in interventional studies of healthy individuals at risk of AD. Given the current lack of
effective AD treatments, the identification of modifiable risk factors associated with development
of presymptomatic AD trajectories should be of considerable interest for AD prevention research.
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